News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Provides Update on Generic Actonel(R) Litigation


5/13/2009 12:02:27 PM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a February 29, 2008 decision by the District Court, which had found Procter & Gamble's U.S. Patent No. 5,538,122 to be valid. As a result of today's decision, Teva expects to market its generic version of Procter & Gamble's Actonel® (Risedronate Sodium) Tablets no later than June 2014, when the patent is otherwise set to expire.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES